156380-34-6

Basic information

• Product Name: tetrahydrofuran-3-yl Methanesulfonate
• Synonyms: tetrahydrofuran-3-yl Methanesulfonate
• CAS NO: 156380-34-6
• Molecular Formula: C₅H₁₀O₄S
• Molecular Weight: 166.1955
• Mol File: 156380-34-6.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tetrahydrofuran-3-yl Methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: tetrahydrofuran-3-yl Methanesulfonate(156380-34-6)
• EPA Substance Registry System: tetrahydrofuran-3-yl Methanesulfonate(156380-34-6)

Safety Data

• Hazardous Substances Data: 156380-34-6(Hazardous Substances Data)

Upstream product

• 453-20-3 3-Hydroxytetrahydrofuran 
• 7143-01-3 Methanesulfonic anhydride 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 14631-44-8 3-cyanotetrahydrofuran 
• 1039632-41-1 (1-(R)-phenylethyl)tetrahydrofuran 
• 1039632-43-3 (1-(S)-phenylethyl)tetrahydrofuran 
• 1029715-63-6 1-(tetrahydrofuran-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 949885-88-5 2-(tetrahydro-furan-3-yl)-malonic acid diethyl ester 

Relevant articles and documents

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Calcium dependent protein kinase 1 (CDPK1) is an essential Ser/Thr kinase that controls invasion and egress by the protozoan parasite Toxoplasma gondii. The Gly gatekeeper of CDPK1 makes it exquisitely sensitive to inhibition by small molecule 1H-pyrazolo

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

COMPOUNDS

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).